Literature DB >> 30069410

Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung.

Kazumi Nishino1, Shuichi Ohe2, Masanori Kitamura3, Kei Kunimasa1, Madoka Kimura1, Takako Inoue1, Motohiro Tamiya1, Toru Kumagai1, Shin-Ichi Nakatsuka3, Taiki Isei2, Fumio Imamura1.   

Abstract

Entities:  

Year:  2018        PMID： 30069410      PMCID： PMC6051859          DOI： 10.21037/jtd.2018.05.104

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  13 in total

1.  Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.

Authors:  Maiana Larsabal; Aurélie Marti; Clément Jacquemin; Jérôme Rambert; Denis Thiolat; Léa Dousset; Alain Taieb; Caroline Dutriaux; Sorilla Prey; Katia Boniface; Julien Seneschal
Journal:  J Am Acad Dermatol       Date:  2017-01-13       Impact factor: 11.527

Review 2.  Vitiligo and depression: a systematic review and meta-analysis of observational studies.

Authors:  Y C Lai; Y W Yew; C Kennedy; R A Schwartz
Journal:  Br J Dermatol       Date:  2017-07-23       Impact factor: 9.302

Review 3.  Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Authors:  Michael A Postow; Robert Sidlow; Matthew D Hellmann
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

4.  Evaluation of Histologically and Histochemically Proven Cases of Vitiligo and its Correlation with CD4+ and CD8+ Lymphocyte Counts using Flow Cytometry.

Authors:  Moninder Kaur; Permeet Kaur Bagga; Tejinder Kaur; Amarjit Singh Kataria
Journal:  J Clin Diagn Res       Date:  2017-05-01

Review 5.  Vitiligo: An Update on Pathophysiology and Treatment Options.

Authors:  Reinhart Speeckaert; Nanja van Geel
Journal:  Am J Clin Dermatol       Date:  2017-12       Impact factor: 7.403

6.  Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.

Authors:  Takeshi Uenami; Yuki Hosono; Mikako Ishijima; Masaki Kanazu; Yuki Akazawa; Yukihiro Yano; Masahide Mori; Toshihiko Yamaguchi; Soichiro Yokota
Journal:  Lung Cancer       Date:  2017-04-27       Impact factor: 5.705

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.

Authors:  Camille Hua; Lise Boussemart; Christine Mateus; Emilie Routier; Céline Boutros; Hugo Cazenave; Roxane Viollet; Marina Thomas; Séverine Roy; Naima Benannoune; Gorana Tomasic; Jean-Charles Soria; Stéphane Champiat; Matthieu Texier; Emilie Lanoy; Caroline Robert
Journal:  JAMA Dermatol       Date:  2016-01       Impact factor: 10.282

9.  Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.

Authors:  Yasuhiro Nakamura; Ryota Tanaka; Yuri Asami; Yukiko Teramoto; Taichi Imamura; Sayuri Sato; Hiroshi Maruyama; Yasuhiro Fujisawa; Taisuke Matsuya; Manabu Fujimoto; Akifumi Yamamoto
Journal:  J Dermatol       Date:  2016-08-11       Impact factor: 4.005

Review 10.  Recent advances in understanding vitiligo.

Authors:  Prashiela Manga; Nada Elbuluk; Seth J Orlow
Journal:  F1000Res       Date:  2016-09-06
View more
  4 in total

Review 1.  Immune checkpoint inhibitor-related dermatologic adverse events.

Authors:  Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2020-05-23       Impact factor: 11.527

2.  Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Authors:  Gregory S Phillips; Jennifer Wu; Matthew D Hellmann; Michael A Postow; Naiyer A Rizvi; Azael Freites-Martinez; Donald Chan; Stephen Dusza; Robert J Motzer; Jonathan E Rosenberg; Margaret K Callahan; Paul B Chapman; Larisa Geskin; Adriana T Lopez; Vanessa A Reed; Gabriella Fabbrocini; Maria Carmela Annunziata; Oluwaseun Kukoyi; Aliyah Pabani; Chih-Hsun Yang; Wen-Hung Chung; Alina Markova; Mario E Lacouture
Journal:  J Clin Oncol       Date:  2019-06-19       Impact factor: 50.717

Review 3.  Targeting the PD-1/PD-L1 Axis in Human Vitiligo.

Authors:  Marcella Willemsen; Cornelis J M Melief; Marcel W Bekkenk; Rosalie M Luiten
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

4.  Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report.

Authors:  Sook Jung Yun; In-Jae Oh; Cheol Kyu Park; Young-Chul Kim; Hyeon Bin Kim; Hee-Kyung Kim; A Ram Hong; In-Young Kim; Sung-Ja Ahn; Kook-Joo Na; Yoo-Duk Choi
Journal:  Transl Lung Cancer Res       Date:  2020-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.